University of Pennsylvania (Enrollment is full, not recruiting)
Welcome,         Profile    Billing    Logout  
 4 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
McCormack, Mary
NCT04081714: Intermediate Expanded Access Protocol CNMAu8.EAP03

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine, University of Texas, Southwestern Medical Center at Dallas
Multiple Sclerosis
 
 
CNMAu8.EAP02, NCT05281484: Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and for ALS

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine
Amyotrophic Lateral Sclerosis
 
 
Jawdat, Omar
COMBAT-ALS, NCT04057898 / 2019-003549-14: Evaluation of MN-166 (ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with ALS

Recruiting
2/3
230
Canada, US
MN-166, ibudilast, placebo
MediciNova
Amyotrophic Lateral Sclerosis
12/25
12/26
EPISOD1, NCT06100276: Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

Recruiting
1/2
20
US
AMT-162
UniQure Biopharma B.V.
Amyotrophic Lateral Sclerosis
09/26
03/31
CNMAu8.EAP02, NCT05281484: Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and for ALS

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine
Amyotrophic Lateral Sclerosis
 
 

Download Options